{"id":15385,"date":"2022-02-09T00:00:00","date_gmt":"2022-02-09T00:00:00","guid":{"rendered":"https:\/\/cms.alj3.clients.lemonhq.io\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/"},"modified":"2026-05-12T11:31:55","modified_gmt":"2026-05-12T11:31:55","slug":"healthcare-for-the-many-not-only-the-few-4","status":"publish","type":"perspectives","link":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/","title":{"rendered":"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9"},"content":{"rendered":"<h4>A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine.<\/h4>\n<p>In June 2021, <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a> and <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a>, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully approved by all relevant authorities &#8211; to a potential 1.5 billion people across the Middle East, Africa and Turkey.<\/p>\n<p>The two oncology programs, aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor and sugemalimab, an anti-PD-L1 antibody, have shown promising Phase 3 data for the treatment of patients with advanced non-small cell lung cancer (NSCLC).\u00a0 \u00a0These therapies have the potential to offer treatment at a fraction of the cost of existing approaches.<\/p>\n<p>This collaboration will see Abdul Latif Jameel Health commercialize the drugs to selected markets throughout the Middle East region, as well as in Turkey and all of Africa, providing access to affordable, safe, effective treatment for thousands of lung cancer patients.<\/p>\n<p>We spoke to <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a>, Chief Executive Officer, EQRx, and <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a>, CEO, Abdul Latif Jameel Health, about the partnership and what it could mean for cancer patients in the target markets.<\/p>\n<h2>Melanie, can you tell us about your mission at EQRx?<\/h2>\n<div id=\"attachment_95745\" style=\"width: 231px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95745\" class=\"size-medium wp-image-95745\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/><p id=\"caption-attachment-95745\" class=\"wp-caption-text\">Melanie Nallicheri,<br \/>CEO, EQRx<\/p><\/div>\n<p><strong>MN: <\/strong>Our mission is to improve health for all through great innovative, affordable medicines:<\/p>\n<ul>\n<li>so that people around the world can access these medicines for chronic or life-threatening diseases or conditions without any barriers;<\/li>\n<li>so prescribers around the world can offer them to their patients without unnecessary administrative challenges; and,<\/li>\n<li>so payers and health systems around the world can make these medicines available to patients in a financially sustainable way.<\/li>\n<\/ul>\n<p>What we are basically saying is, we want to make innovative, life-enhancing medicines available and accessible to patients all over the world.<\/p>\n<h2>Why are the issues of accessibility and affordability such big problems in the pharmaceutical industry?<\/h2>\n<p><strong>MN: <\/strong>Our understanding of medicine, biology and data science has developed enormously in recent years. \u00a0Things we can do today would have been seen as science fiction a decade or two ago. \u00a0What usually happens\u00a0 as technology moves forward, costs \u2013 or at least consumer prices \u2013 come down. \u00a0But in healthcare, costs have actually gone up. \u00a0This means our understanding and our capabilities have increased, but the accessibility and affordability of these new solutions has decreased. \u00a0We could see this was wrong, and we saw an opportunity to do things differently by building a successful business at scale to change this dynamic.<\/p>\n<div id=\"attachment_95752\" style=\"width: 283px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95752\" class=\"size-medium wp-image-95752\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/><p id=\"caption-attachment-95752\" class=\"wp-caption-text\">Dr. Akram Bouchenaki,<br \/>CEO, Abdul Latif Jameel Health<\/p><\/div>\n<p><strong>AB: <\/strong>To add to Melanie\u2019s point, there is an incredible unmet medical need for these drugs.\u00a0 If you look at the Gulf region, which generally has a good level of healthcare, lung cancer is the second most common cancer in men, and it is the leading cause of death by cancer in men.\u00a0 Up to 80 percent of cases are diagnosed at advanced stages, and the five-year survival is as low as 10 to 20 percent.<\/p>\n<p>This is why it is absolutely critical to massively expand access to these therapies.\u00a0 That\u2019s the vision that we\u2019re trying to implement.<\/p>\n<h2>This isn\u2019t a new problem, so what is different about EQRx\u2019s approach to addressing it?<\/h2>\n<p><strong>MN: <\/strong>We recognized that to make a real difference, you need a significant portfolio, or catalog, of medicines. \u00a0This allows you to offer many choices for treating chronic or life-threatening diseases and enables you to make the greatest impact. \u00a0Instead of starting with one or two drugs, we wanted to start with 10, 20, 30, focusing on critical areas like oncology and immune-inflammatory diseases.<\/p>\n<p>We are also coming at the problem from a different perspective, from the basis of a shared objective with prescribers and payers. \u00a0Normally a manufacturer will launch a great new drug, but they keep the price high to maximize their profits and keep their shareholders happy. \u00a0Prescribers want to offer this drug to their patients, while payers \u2013 like health insurers or national health schemes \u2013 want to make it available to their members and communities. \u00a0The problem is, the cost is so high they can only afford to prescribe to a certain number of people, otherwise it would blow their budget. \u00a0This means they have to restrict who can benefit from these drugs.\u00a0 In effect, the objectives of the manufacturers, the prescribers\/payers and the patients are at odds with each other.<\/p>\n<p>Our approach is to work towards a <em>shared objective<\/em> of making these medicines as widely available as possible. \u00a0To do this, we intend to make our pricing\u00a0 transparent, simple and radically lower. \u00a0We will benefit from selling more of our medicines, prescribers and payers benefit from offering these treatments to more people without breaking their budgets, and patients benefit from having access to life-enhancing healthcare.<\/p>\n<h2>How big a difference could this make for health systems as well as for patients?<\/h2>\n<p><strong>MN: <\/strong>The potential benefits are enormous.\u00a0 Our mission is to offer life-changing medicines at radically lower prices.\u00a0 By radically lower, we\u2019re talking a quarter, a third, a half lower.\u00a0 That makes a significant difference.\u00a0 For example, say there is a total global spend for a specific drug of US$ 10 billion, which isn\u2019t inconceivable for many immune-inflammatory diseases.\u00a0 Our drug might be priced at a third of the price of the current drug, so in a market of US$ 10 billion, there is immediately a potential saving of over US$ 6.6 billion.\u00a0 Of course, we\u2019re never going to own 100% of a market, but even if we only had 15% of the market \u2013 US$ 1.5 billion \u2013 by offering our drug at one-third of the price, that\u2019s still US$500 million in revenue for us and a saving of US$ 1 billion for the health system.\u00a0 So you can see how we can potentially build a great business yet also generate significant value for all of the other stakeholders in our ecosystem, not least the patients, who will have access to treatments that may have been previously unavailable to them.<\/p>\n<div id=\"attachment_95724\" style=\"width: 2277px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95724\" class=\"size-full wp-image-95724\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/><p id=\"caption-attachment-95724\" class=\"wp-caption-text\">Pictured (L-R) Alexis Borisy, Executive Chairman, Board of Directors &amp; Melanie Nallicheri, Chief Executive Officer EQRx<br \/>Photo credit \u00a9 Fierce Biotech.<\/p><\/div>\n<h2>How has EQRx been able to overcome the barriers that have stopped someone doing this before?<\/h2>\n<p><strong>MN: <\/strong>There are three core pillars in our business model that we believe will enable us to do this. \u00a0The first is that, right from day one, we have had a laser-sharp focus on creating a completely different cost structure.\u00a0 We are a new business, so we\u2019ve been able to create that structure from the ground up right across the organization.\u00a0 Second, we are creating operational processes that leverage everything we have at our disposal as an industry to lower the cost of developing the medicine. \u00a0For instance, you can use remote approaches to monitor patients during a clinical trial, which means you can conduct trials much faster and more efficiently, which reduces costs.\u00a0 Lastly, because of this unique business model, we don\u2019t need the typical salesforce-driven, high-promotion approach to selling drugs.\u00a0 Our partners should be creating the pull-through and the access to our medicines, as opposed to us sending hundreds of salespeople to persuade people to buy them.\u00a0 This kind of market-driven model has not existed before in the global healthcare sector.<\/p>\n<h2>Akram, what was it about EQRx that convinced you they would be good partners for Abdul Latif Jameel Health?<\/h2>\n<p><strong>AB<\/strong>: As we were looking to become an investor in EQRx, we found a great alignment with the vision, the values and the overall purpose of EQRx. \u00a0Abdul Latif Jameel Health aims to be a bridge to accelerate access to innovative therapies in the global south. \u00a0\u00a0The two key words there are \u2018accelerate&#8217; and \u2018access\u2019.\u00a0 We want to get vital medicines \u00a0to people faster and make them accessible to more people.\u00a0 Affordability is a key part of that, but price is not the only factor preventing medicines reaching those who need them.\u00a0 I\u2019ve been in situations in my career where we have donated tons of drugs to treat infectious disease to countries where prevalence rates were very high, but unfortunately the drugs never made it to the patients who needed them. \u00a0So, there is more than just an affordability issue to address.<\/p>\n<p>The other thing we really liked with the EQRx approach is that we saw a great alignment with the innovative business model they are building, the way they\u2019re focusing on the right stakeholders for the future. \u00a0It is a vision and a strategy that we very much support and look forward to implementing in our part of the world.<\/p>\n<h2>Melanie, your first two products are both cancer drugs &#8211; aumolertinib and sugemalimab. Why did you choose to start with these two?<\/h2>\n<p><strong>MN: <\/strong>When we first started, we said we wanted to have our first drug available to patients within five years.\u00a0 That was part of our thinking when we were scanning the market for medicines to bring into our portfolio.\u00a0 Both aumolertinib and sugemalimab are for non-small-cell lung cancer, as well as other cancers.\u00a0 Aumolertinib is a targeted therapy in oncology for patients with EFGR-driven mutations.\u00a0 Sugemalimab is an immunotherapy. \u00a0In cancer, it\u2019s the largest drug class that we know today.<\/p>\n<p>We were very excited about these drugs, both of which have been shown to have excellent efficacy and a strong tolerability profile.<\/p>\n<p>Not only that, these two medicines could be available as early as 2023, which is much sooner than our original five-year target.\u00a0 This means we can start having conversations with regulatory agencies around the world, and with our partners around the world, to start the process of getting these drugs to the people that need them.\u00a0 It\u2019s the ideal scenario: a great medicine with a great tolerability profile, much sooner than we had originally anticipated. \u00a0That\u2019s why we were so excited about these two therapeutics.<\/p>\n<h2>Akram, how do you plan to leverage Abul Latif Jameel\u2019s global footprint to get these drugs to those who need them?<\/h2>\n<p><strong>AB:<\/strong> \u00a0This is the kind of challenge for which Abdul Latif Jameel Health was designed.\u00a0 It was the vision of <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> that we become a critical part of the innovation chain, because innovation is not just what happens in the lab.\u00a0 That\u2019s the starting point, of course, but innovation is also about finding new ways, faster and more effective ways, to deliver those therapies to patients.\u00a0 We see ourselves as the deliverers of that promise of innovation.\u00a0 These drugs are going to be absolutely central in transforming patient care, in prolonging life, in making cancer treatment better tolerated.\u00a0 The promise is there, and we see delivery as an integral part of that innovation journey.<\/p>\n<h2>What do you see as the biggest challenges for EQRx in achieving your ambitions?<\/h2>\n<p><strong>MN<\/strong>: \u00a0Our first challenge is to develop our catalogue of medicines and build up our organization at scale.\u00a0 To do that you need to be able to do two things. \u00a0One, you need to attract some of the best talent in the entire industry. \u00a0Two, you need to be able to mobilize significant capital to build an enterprise rapidly at scale. \u00a0We\u2019ve been working really diligently from the get-go on both. \u00a0On the people front, we have established a talent brand that\u2019s really unique, both because of our social mission, which is really exciting to people, and also because of the culture at EQRx that rewards enterprise and innovation. \u00a0People are encouraged and empowered to try to do things differently, even if we know that some of the ideas might not work.<\/p>\n<p><strong>AB: \u00a0<\/strong>For us, the challenge is to implement this uniquely innovative and disruptive model.\u00a0 We need to go out and change people\u2019s perceptions about how the drug market works.\u00a0 We don\u2019t want to have armies of sales reps hovering around corridors in hospitals, which is a huge waste of productive time, but rather focus on service, education, distribution.\u00a0 Partnering with healthcare authorities, regulators, and healthcare providers in general is going to be a key success factor for us as we build a new model of medicine where patients are actors in their own health.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-95731 aligncenter\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\n<h2>Finally, what\u2019s next for you both?<\/h2>\n<p><strong>MN:<\/strong> \u00a0We\u2019ll be focusing on building our catalogue and our organization.\u00a0 We have over 10 programs in our portfolio right now. \u00a0Of these, five are clinical-stage programs, including aumolertinib and sugemalimab.\u00a0 We also have another immunotherapy option in our portfolio. \u00a0We have a breast cancer drug, and we have a drug for major immuno-inflammatory diseases, like rheumatoid arthritis and atopic dermatitis. \u00a0After those, we have several earlier-stage programs that we\u2019re developing. \u00a0These include both oncology and immuno-inflammatory diseases, and then most recently, we\u2019ve announced several drug engineering collaborations with companies.\u00a0 By 2025 or 2026, we expect to be addressing more than 20% of the spend of a trillion-dollar global branded drug market. \u00a0And that\u2019s a hugely exciting prospect.<\/p>\n<p><strong>AB<\/strong>: \u00a0We can\u2019t wait to be part of that journey.\u00a0 We\u2019re looking forward to working with Melanie and the team at EQRx and really starting to put our strategy into practice.\u00a0 That\u2019s when the work really starts.\u00a0 We\u2019re super-excited. \u00a0We would love to see patients get access to these exciting new drugs as soon as we possibly can, and we\u2019ll do all we can to achieve that over the next few years, and hopefully beyond.<\/p>\n","protected":false},"featured_media":15377,"menu_order":0,"template":"","class_list":["post-15385","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel\" \/>\n<meta property=\"og:description\" content=\"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Abdul Latif Jameel\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T11:31:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1511\" \/>\n\t<meta property=\"og:image:height\" content=\"868\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/\",\"url\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/\",\"name\":\"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel\",\"isPartOf\":{\"@id\":\"https:\/\/10.0.2.222\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"datePublished\":\"2022-02-09T00:00:00+00:00\",\"dateModified\":\"2026-05-12T11:31:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage\",\"url\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"contentUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"width\":1511,\"height\":868},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/10.0.2.222\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/10.0.2.222\/en\/#website\",\"url\":\"https:\/\/10.0.2.222\/en\/\",\"name\":\"Abdul Latif Jameel\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/10.0.2.222\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel","og_description":"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]","og_url":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/","og_site_name":"Abdul Latif Jameel","article_modified_time":"2026-05-12T11:31:55+00:00","og_image":[{"width":1511,"height":868,"url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/","url":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/","name":"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9 - Abdul Latif Jameel","isPartOf":{"@id":"https:\/\/10.0.2.222\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage"},"image":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage"},"thumbnailUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","datePublished":"2022-02-09T00:00:00+00:00","dateModified":"2026-05-12T11:31:55+00:00","breadcrumb":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#primaryimage","url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","contentUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","width":1511,"height":868},{"@type":"BreadcrumbList","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/perspectives\/healthcare-for-the-many-not-only-the-few-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/10.0.2.222\/en\/"},{"@type":"ListItem","position":2,"name":"Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/10.0.2.222\/en\/#website","url":"https:\/\/10.0.2.222\/en\/","name":"Abdul Latif Jameel","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/10.0.2.222\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"post-meta-fields":{"_wp_page_template":["default"],"_published_date":["field_6057129b493f5"],"published_date":["20220209"],"_location":["field_601267396ce72"],"location":["Dubai, EAU"],"_featured":["field_601a3b473c5c5"],"featured":["0"],"_footnotes":["field_66fd39afb9383"],"footnotes":[""],"_business_sector":["field_66f6b5bcac8cb"],"business_sector":["Sant\u00e9"],"_content_series":["field_66fe3c439f8f6"],"content_series":[""],"_old_post_id":["field_66fe3fd59f8f7"],"old_post_id":["95764"],"_short_title":["field_60925d67125ef"],"short_title":["Soins de sant\u00e9 pour tous, pas seulement pour une minorit\u00e9"],"_summary":["field_6019304103a20"],"summary":["<p>Questions-r\u00e9ponses avec Melanie Nallicheri, PDG d\u2019EQRx, en route pour changer la m\u00e9decine.<\/p>"],"_mobile_featured_image":["field_66f6b4bee65f3"],"mobile_featured_image":["https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg"],"_push_notification":["field_66f6b47de65f1"],"push_notification":[""],"_publish_mobile":["field_66f6b491e65f2"],"publish_mobile":["0"],"_status":["field_652694983fe12"],"status":["publish"],"_thumbnail_id":["15377"],"_wpml_word_count":["{\"total\":2437,\"to_translate\":{\"ar\":2437,\"zh-hans\":2437,\"fr\":2437,\"ja\":2437,\"es\":2437,\"tr\":2437}}"],"_last_translation_edit_mode":["native-editor"],"amazonS3_cache":["a:12:{s:88:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:96:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:98:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:119:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:113:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:121:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:160:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:162:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:73:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}s:75:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}}"],"_edit_lock":["1778585409:22"],"content":["<h4>Questions-r\u00e9ponses avec Melanie Nallicheri, PDG d\u2019EQRx, en route pour changer la m\u00e9decine.<\/h4>\r\n<p>En juin 2021, <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a> et <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a>, une soci\u00e9t\u00e9 engag\u00e9e dans le d\u00e9veloppement et la fabrication de m\u00e9dicaments r\u00e9volutionnaires \u00e0 des prix plus bas, ont sign\u00e9 une collaboration strat\u00e9gique pour la distribution de deux nouveaux m\u00e9dicaments abordables contre le cancer du poumon, une fois qu\u2019ils auront \u00e9t\u00e9 enti\u00e8rement approuv\u00e9s par toutes les autorit\u00e9s comp\u00e9tentes, pour un march\u00e9 de 1,5\u00a0milliard de personnes au Moyen-Orient, en Afrique et en Turquie.<\/p>\r\n<p>Deux programmes d\u2019oncologie, aumolertinib, un inhibiteur du r\u00e9cepteur du facteur de croissance \u00e9pidermique (RFCE) et sugemalimab, un anticorps anti-PD-L1, ont donn\u00e9 des r\u00e9sultats de phase 3\u00a0prometteurs pour le traitement des patients atteints d\u2019un cancer du poumon non \u00e0 petites cellules (CPNPC) avanc\u00e9. Ces th\u00e9rapies peuvent offrir un traitement \u00e0 une fraction du co\u00fbt des traitements traditionnels.<\/p>\r\n<p>Cette nouvelle collaboration strat\u00e9gique permettra \u00e0 Abdul Latif Jameel Health de commercialiser ces m\u00e9dicaments sur certains march\u00e9s dans tout le Moyen-Orient, ainsi qu\u2019en Turquie et dans toute l\u2019Afrique, offrant ainsi \u00e0 des milliers de patients atteints d\u2019un CPNPC avanc\u00e9 l\u2019acc\u00e8s \u00e0 un traitement abordable.<\/p>\r\n<p>Nous avons parl\u00e9 \u00e0 <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a>, pr\u00e9sidente-directrice g\u00e9n\u00e9rale d\u2019EQRx, et <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a>, PDG d\u2019Abdul Latif Jameel Health, au sujet du partenariat et de ce qu\u2019il pourrait signifier pour les patients atteints de cancer sur les march\u00e9s cibles.<\/p>\r\n<h2>Melanie, pouvez-vous nous parler de votre mission chez EQRx ?<\/h2>\r\n\r\n[caption id=\"attachment_95748\" align=\"alignright\" width=\"221\"]<img class=\"size-medium wp-image-95748\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/> Melanie Nallicheri,<br \/>\r\npr\u00e9sidente-directrice g\u00e9n\u00e9rale d\u2019EQRx[\/caption]\r\n\r\n<p><strong>MN\u00a0:<\/strong> Notre mission est d\u2019am\u00e9liorer la sant\u00e9 de tous gr\u00e2ce \u00e0 des m\u00e9dicaments innovants et abordables\u00a0:<\/p>\r\n<ul>\r\n\t<li>afin que les personnes du monde entier puissent acc\u00e9der sans aucune contrainte \u00e0 ces m\u00e9dicaments pour des maladies ou affections chroniques ou potentiellement l\u00e9tales\u00a0;<\/li>\r\n\t<li>afin que les prescripteurs du monde entier puissent les offrir \u00e0 leurs patients sans difficult\u00e9s administratives inutiles\u00a0; et<\/li>\r\n\t<li>afin que les payeurs et les syst\u00e8mes de sant\u00e9 du monde entier puissent mettre ces m\u00e9dicaments \u00e0 la disposition des patients d\u2019une mani\u00e8re financi\u00e8rement durable.<\/li>\r\n<\/ul>\r\n<p>En r\u00e9sum\u00e9, nous voulons mettre \u00e0 la disposition des patients dans le monde entier des m\u00e9dicaments innovants qui am\u00e9liorent la vie.<\/p>\r\n<h2>Pourquoi les probl\u00e8mes d\u2019accessibilit\u00e9 et de co\u00fbt sont-ils si importants dans l\u2019industrie pharmaceutique ?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Notre compr\u00e9hension de la m\u00e9decine, de la biologie et de la science des donn\u00e9es s\u2019est d\u00e9velopp\u00e9e de mani\u00e8re consid\u00e9rable ces derni\u00e8res ann\u00e9es. Ce que nous pouvons faire aujourd\u2019hui aurait \u00e9t\u00e9 consid\u00e9r\u00e9 comme de la science-fiction il y a une d\u00e9cennie ou deux. G\u00e9n\u00e9ralement, \u00e0 mesure que la technologie progresse, les co\u00fbts, ou du moins les prix \u00e0 la consommation, diminuent. Mais dans les soins de sant\u00e9, les co\u00fbts ont en fait augment\u00e9. Cela signifie que notre compr\u00e9hension et nos capacit\u00e9s ont augment\u00e9, mais que l\u2019acc\u00e8s \u00e0 ces nouvelles solutions a diminu\u00e9. Nous voulons changer cela, et nous avons identifi\u00e9 une opportunit\u00e9 de faire les choses diff\u00e9remment en construisant une entreprise prosp\u00e8re \u00e0 grande \u00e9chelle, afin de changer cette dynamique.<\/p>\r\n\r\n[caption id=\"attachment_95755\" align=\"alignright\" width=\"273\"]<img class=\"size-medium wp-image-95755\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/> Dr Akram Bouchenaki<br \/>\r\nPDG d\u2019Abdul Latif Jameel Health[\/caption]\r\n\r\n<p><strong>AB\u00a0: <\/strong>Pour rejoindre Melanie, il existe une incroyable demande insatisfaite pour ces m\u00e9dicaments. Si vous examinez la r\u00e9gion CCG (d\u00e9finir\u00a0?), qui a g\u00e9n\u00e9ralement un bon niveau de soins de sant\u00e9, le cancer du poumon est le deuxi\u00e8me cancer le plus fr\u00e9quent chez les hommes, et la principale cause de d\u00e9c\u00e8s par cancer chez les hommes. Jusqu\u2019\u00e0 80\u00a0% des cas sont diagnostiqu\u00e9s \u00e0 des stades avanc\u00e9s, et la survie \u00e0 cinq ans n\u2019est que de 10\u00a0\u00e0 20\u00a0%.<\/p>\r\n<p>C\u2019est pourquoi il est absolument essentiel d\u2019\u00e9largir massivement l\u2019acc\u00e8s \u00e0 ces traitements. C\u2019est la vision que nous essayons de mettre en \u0153uvre.<\/p>\r\n<h2>Il ne s\u2019agit pas d\u2019un nouveau probl\u00e8me, alors en quoi l\u2019approche d\u2019EQRx pour le r\u00e9soudre est-elle diff\u00e9rente ?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Nous avons compris que pour faire une r\u00e9elle diff\u00e9rence, vous avez besoin d\u2019un portefeuille, ou catalogue de m\u00e9dicaments, important. Cela vous permet d\u2019offrir de nombreuses options pour le traitement des maladies chroniques ou potentiellement mortelles, et vous permet d\u2019avoir un fort impact. Au lieu de commencer avec un ou deux m\u00e9dicaments, nous avons voulu commencer par dix, vingt, ou trente, en nous concentrant sur des domaines critiques comme l\u2019oncologie et les maladies immuno-inflammatoires.<\/p>\r\n<p>Nous abordons \u00e9galement le probl\u00e8me d\u2019un point de vue diff\u00e9rent, dans l\u2019optique d\u2019un objectif partag\u00e9 avec les prescripteurs et les payeurs. Normalement, quand un fabricant lance un nouveau m\u00e9dicament performant, il le vend \u00e0 un prix \u00e9lev\u00e9 pour maximiser ses b\u00e9n\u00e9fices et satisfaire ses actionnaires. Les prescripteurs veulent proposer ce m\u00e9dicament \u00e0 leurs patients, tandis que les payeurs, comme les assureurs de sant\u00e9 ou les r\u00e9gimes de sant\u00e9 nationaux, veulent le mettre \u00e0 disposition de leurs membres et de leurs communaut\u00e9s. Le probl\u00e8me, c\u2019est que son co\u00fbt est si \u00e9lev\u00e9 qu\u2019ils ne peuvent se permettre de le prescrire qu\u2019\u00e0 un certain nombre de personnes, sous peine de d\u00e9passer leur budget. Cela signifie que le nombre de personnes pouvant b\u00e9n\u00e9ficier de ces m\u00e9dicaments est limit\u00e9. Les objectifs des fabricants, des prescripteurs\/payeurs et des patients sont donc contradictoires.<\/p>\r\n<p>Notre approche consiste \u00e0 travailler vers un <em>objectif partag\u00e9,<\/em> qui cherche \u00e0 rendre ces m\u00e9dicaments aussi largement accessibles que possible. Pour ce faire, nous avons l\u2019intention de faire en sorte que nos prix soient transparents, simples et radicalement inf\u00e9rieurs. Nous pourrons vendre un plus grand nombre de nos m\u00e9dicaments, tandis que les prescripteurs et payeurs de ces traitements pourront les proposer \u00e0 un plus grand nombre de personnes sans d\u00e9passer leurs budgets, et que les patients b\u00e9n\u00e9ficieront de soins de sant\u00e9 am\u00e9liorant la vie.<\/p>\r\n<h2>Quelle diff\u00e9rence cela pourrait-il faire pour les syst\u00e8mes de sant\u00e9 ainsi que pour les patients\u00a0?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Les avantages potentiels sont \u00e9normes. Notre mission est d\u2019offrir des m\u00e9dicaments r\u00e9volutionnaires \u00e0 des prix radicalement inf\u00e9rieurs. \u00ab\u00a0Radicalement inf\u00e9rieur\u00a0\u00bb signifie 25, 30 ou 50\u00a0% moins cher. C\u2019est une diff\u00e9rence significative. Par exemple, imaginons une d\u00e9pense mondiale totale de 10\u00a0milliards USD pour un m\u00e9dicament sp\u00e9cifique, ce qui n\u2019est pas inconcevable pour de nombreuses maladies immuno-inflammatoires. Notre m\u00e9dicament pourrait \u00eatre factur\u00e9 \u00e0 un tiers du prix du m\u00e9dicament actuel, donc sur un march\u00e9 de 10\u00a0milliards USD, cela repr\u00e9sente une \u00e9conomie potentielle imm\u00e9diate de plus de 6,6\u00a0milliards USD. Bien s\u00fbr, nous n\u2019aurons jamais 100\u00a0% d\u2019un march\u00e9, mais m\u00eame si nous n\u2019en avons que 15\u00a0%, si nous offrons notre m\u00e9dicament \u00e0 un tiers du prix, 1,5\u00a0milliard USD c\u2019est quand m\u00eame 500\u00a0millions USD de revenus pour nous et une \u00e9conomie de 1\u00a0milliard USD pour le syst\u00e8me de sant\u00e9. Vous voyez donc comment nous pouvons potentiellement construire une grande entreprise tout en g\u00e9n\u00e9rant une valeur significative pour toutes les autres parties prenantes de notre \u00e9cosyst\u00e8me, notamment les patients, qui auront acc\u00e8s \u00e0 des traitements qui n\u2019\u00e9taient pas disponibles jusque l\u00e0.<\/p>\r\n\r\n[caption id=\"attachment_95727\" align=\"aligncenter\" width=\"2267\"]<img class=\"size-full wp-image-95727\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/> Photo (L-R) Alexis Borisy, pr\u00e9sident ex\u00e9cutif, conseil d\u2019administration et Melanie Nallicheri, pr\u00e9sidente-directrice g\u00e9n\u00e9rale d\u2019EQRx<br \/>\r\nCr\u00e9dit photo \u00a9 Fierce Biotech.[\/caption]\r\n\r\n<h2>Comment EQRx a-t-elle \u00e9t\u00e9 capable de surmonter les obstacles qui ont emp\u00each\u00e9 de faire cela auparavant ?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Nous pensons qu\u2019il existe trois piliers fondamentaux dans notre mod\u00e8le d\u2019entreprise qui nous permettront de faire cela. Le premier est que, d\u00e8s le premier jour, nous nous sommes vraiment concentr\u00e9s sur une structure de co\u00fbts compl\u00e8tement diff\u00e9rente. Comme nous sommes une nouvelle entreprise, nous avons \u00e9t\u00e9 en mesure de cr\u00e9er cette structure \u00e0 partir de z\u00e9ro dans l\u2019ensemble de l\u2019organisation.<\/p>\r\n<p>Deuxi\u00e8mement, nous cr\u00e9ons des processus op\u00e9rationnels qui exploitent tout ce que nous avons \u00e0 notre disposition en tant qu\u2019industrie pour r\u00e9duire le co\u00fbt de d\u00e9veloppement du m\u00e9dicament. Par exemple, il est possible d\u2019utiliser des approches \u00e0 distance pour surveiller les patients au cours d\u2019un essai clinique, ce qui signifie que l\u2019on peut mener les essais beaucoup plus rapidement et plus efficacement, ce qui r\u00e9duit les co\u00fbts.<\/p>\r\n<p>Enfin, gr\u00e2ce \u00e0 ce mod\u00e8le commercial unique, nous n\u2019avons pas besoin de l\u2019approche typique de la vente de m\u00e9dicaments, ax\u00e9e sur la force de vente et la promotion forte. Plut\u00f4t que d\u2019envoyer des centaines de vendeurs convaincre les gens d\u2019acheter nos m\u00e9dicaments, nous chargeons nos partenaires de cr\u00e9er l\u2019acc\u00e8s \u00e0 ceux-ci. Ce type de mod\u00e8le ax\u00e9 sur le march\u00e9 n\u2019existait pas auparavant dans le secteur mondial de la sant\u00e9.<\/p>\r\n<h2>Akram, qu\u2019est-ce qui vous a convaincu qu\u2019EQRx serait un bon partenaire pour Abdul Latif Jameel Health\u00a0?<\/h2>\r\n<p><strong>AB\u00a0:<\/strong> Alors que nous cherchions \u00e0 investir dans EQRx, nous avons d\u00e9couvert que notre vision, nos valeurs et notre objectif global \u00e9taient align\u00e9s. Abdul Latif Jameel Health vise \u00e0 \u00eatre un pont pour acc\u00e9l\u00e9rer l\u2019acc\u00e8s aux th\u00e9rapies innovantes dans l\u2019h\u00e9misph\u00e8re sud. Les deux mots cl\u00e9s sont \u00ab\u00a0acc\u00e9l\u00e9rer\u00a0\u00bb et \u00ab\u00a0acc\u00e8s\u00a0\u00bb. Nous voulons fournir des m\u00e9dicaments vitaux plus rapidement et les rendre accessibles au plus grand nombre. L\u2019abordabilit\u00e9 est un \u00e9l\u00e9ment cl\u00e9, mais le prix n\u2019est pas le seul facteur emp\u00eachant les m\u00e9dicaments de parvenir \u00e0 ceux qui en ont besoin.<\/p>\r\n<p>Au cours de ma carri\u00e8re, j\u2019ai \u00e9t\u00e9 dans des situations o\u00f9 nous avons fait don de tonnes de m\u00e9dicaments pour traiter des maladies infectieuses dans des pays o\u00f9 les taux de pr\u00e9valence \u00e9taient tr\u00e8s \u00e9lev\u00e9s, mais malheureusement, les m\u00e9dicaments n\u2019ont jamais \u00e9t\u00e9 distribu\u00e9s aux patients qui en avaient besoin. Il y a donc plus qu\u2019un simple probl\u00e8me d\u2019accessibilit\u00e9 financi\u00e8re \u00e0 r\u00e9soudre.<\/p>\r\n<p>Ce que nous appr\u00e9cions \u00e9galement beaucoup dans l\u2019approche d\u2019EQRx, c\u2019est que son mod\u00e8le commercial innovant, et la fa\u00e7on dont elle se concentre sur les parties prenantes ad\u00e9quates pour l\u2019avenir, nous correspondent. Il s\u2019agit d\u2019une vision et d\u2019une strat\u00e9gie que nous partageons et que nous sommes impatients de mettre en \u0153uvre dans notre partie du monde.<\/p>\r\n<h2>Melanie, vos deux premiers produits, aumolertinib et sugemalimab, sont tous deux des m\u00e9dicaments anticanc\u00e9reux. Pourquoi avez-vous choisi de commencer par ces deux produits\u00a0?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Lorsque nous avons commenc\u00e9, nous voulions que notre premier m\u00e9dicament soit disponible pour les patients dans les cinq ans. Nous avons tenu cela en compte lorsque nous avons examin\u00e9 le march\u00e9 des m\u00e9dicaments \u00e0 int\u00e9grer \u00e0 notre portefeuille. Aumolertinib et sugemalimab sont tous deux destin\u00e9s au cancer bronchique non \u00e0 petites cellules, ainsi qu\u2019\u00e0 d\u2019autres cancers. Aumolertinib est une th\u00e9rapie oncologique cibl\u00e9e pour les patients pr\u00e9sentant des mutations induites par EFGR, tandis que sugemalimab est une immunoth\u00e9rapie. C\u2019est la plus grande classe de m\u00e9dicaments pour le cancer que nous connaissons aujourd\u2019hui.<\/p>\r\n<p>Ces m\u00e9dicaments nous ont enthousiasm\u00e9s, car ils ont tous deux d\u00e9montr\u00e9 une excellente efficacit\u00e9 et un fort profil de tol\u00e9rance.<\/p>\r\n<p>De plus, ces deux m\u00e9dicaments pourraient \u00eatre disponibles d\u00e8s 2023, ce qui est bien plus t\u00f4t que notre objectif initial de cinq ans. Cela signifie que nous pouvons commencer \u00e0 discuter avec les agences r\u00e9glementaires du monde entier, et avec nos partenaires du monde entier, pour entamer le processus de distribution de ces m\u00e9dicaments aux personnes qui en ont besoin. C\u2019est le sc\u00e9nario id\u00e9al\u00a0: un excellent m\u00e9dicament avec un profil de tol\u00e9rance \u00e9lev\u00e9, bien plus t\u00f4t que ce que nous avions pr\u00e9vu au d\u00e9part. C\u2019est pourquoi ces deux traitements nous enthousiasment tellement.<\/p>\r\n<h2>Akram, comment pr\u00e9voyez-vous d\u2019exploiter l\u2019envergure mondiale d\u2019Abdul Latif Jameel pour offrir ces m\u00e9dicaments \u00e0 ceux qui en ont besoin ?<\/h2>\r\n<p><strong>AB\u00a0:<\/strong> C\u2019est le type de d\u00e9fi pour lequel Abdul Latif Jameel Health a \u00e9t\u00e9 con\u00e7ue. <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> souhaitait que nous devenions une partie essentielle de la cha\u00eene d\u2019innovation, car l\u2019innovation n\u2019est pas seulement ce qui se passe dans le laboratoire. C\u2019est le point de d\u00e9part, bien s\u00fbr, mais l\u2019innovation consiste \u00e9galement \u00e0 trouver de nouvelles fa\u00e7ons, plus rapides et plus efficaces, d\u2019administrer ces th\u00e9rapies aux patients. Nous nous consid\u00e9rons comme ceux qui vont tenir cette promesse d\u2019innovation. Ces m\u00e9dicaments seront absolument essentiels pour transformer les soins aux patients, prolonger leur vie, et am\u00e9liorer la tol\u00e9rance au traitement contre le cancer. La promesse est l\u00e0, et nous consid\u00e9rons sa mise en oeuvre comme une partie int\u00e9grante de ce parcours d\u2019innovation.<\/p>\r\n<h2>\u00a0Qu\u2019est-ce que vous consid\u00e9rez comme les plus grands d\u00e9fis pour EQRx dans la r\u00e9alisation de vos ambitions\u00a0?<\/h2>\r\n<p><strong>MN<\/strong>\u00a0: Notre premier d\u00e9fi consiste \u00e0 d\u00e9velopper notre catalogue de m\u00e9dicaments et \u00e0 d\u00e9velopper notre organisation \u00e0 grande \u00e9chelle. Pour ce faire, il faut \u00eatre capable de faire deux choses. Tout d\u2019abord, il faut attirer certains des meilleurs talents dans l\u2019ensemble du secteur. Deuxi\u00e8mement, il faut \u00eatre capable de mobiliser des capitaux importants pour construire une entreprise rapidement et \u00e0 grande \u00e9chelle. D\u00e8s le d\u00e9part, nous avons travaill\u00e9 avec beaucoup d\u2019empressement sur ces deux points. En termes de personnes, nous avons \u00e9tabli une marque de talent vraiment unique, \u00e0 la fois du fait de notre mission sociale vraiment passionnante, et \u00e9galement en raison de la culture d\u2019EQRx, qui r\u00e9compense l\u2019initiative et l\u2019innovation. Nos collaborateurs sont motiv\u00e9s et sentent qu\u2019ils ont les moyens d\u2019essayer de faire les choses diff\u00e9remment, m\u00eame si nous savons que certaines des id\u00e9es risquent de ne pas fonctionner.<\/p>\r\n<p><strong>AB\u00a0:<\/strong> Pour nous, le d\u00e9fi consiste \u00e0 mettre en \u0153uvre ce mod\u00e8le innovant unique qui va changer les choses. Nous devons changer la perception qu\u2019ont les gens du fonctionnement du march\u00e9 des m\u00e9dicaments. Nous ne voulons pas d\u2019arm\u00e9es de repr\u00e9sentants commerciaux dans les couloirs des h\u00f4pitaux, car cela repr\u00e9sente un \u00e9norme gaspillage de temps productif, et nous pr\u00e9f\u00e9rons nous concentrer sur le service, l\u2019\u00e9ducation, et la distribution. Le partenariat avec les autorit\u00e9s sanitaires, les r\u00e9gulateurs et les prestataires de soins de sant\u00e9 en g\u00e9n\u00e9ral sera un facteur de r\u00e9ussite cl\u00e9 pour nous tandis que nous \u00e9laborons un nouveau mod\u00e8le de m\u00e9decine dans lequel les patients sont des acteurs de leur propre sant\u00e9.<\/p>\r\n<p><img class=\"aligncenter size-full wp-image-95734\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\r\n<h2>Enfin, quelle est la prochaine \u00e9tape pour vous deux ?<\/h2>\r\n<p><strong>MN\u00a0:<\/strong> Nous nous concentrerons sur le d\u00e9veloppement de notre catalogue et de notre organisation. Nous avons actuellement plus de 10\u00a0programmes dans notre portefeuille. Parmi ces programmes, cinq sont des programmes de stade clinique, dont aumolertinib et sugemalimab. Nous avons \u00e9galement une autre option d\u2019immunoth\u00e9rapie dans notre portefeuille. Nous avons un m\u00e9dicament contre le cancer du sein, et un autre pour les maladies immuno-inflammatoires majeures, comme la polyarthrite rhumato\u00efde et la dermatite atopique. De plus, nous sommes en train de d\u00e9velopper plusieurs programmes d\u2019\u00e9tapes ant\u00e9rieures. Ceux-ci comprennent \u00e0 la fois l\u2019oncologie et les maladies immuno-inflammatoires, et plus r\u00e9cemment, nous avons annonc\u00e9 plusieurs collaborations d\u2019ing\u00e9nierie m\u00e9dicamenteuse avec des entreprises. D\u2019ici 2025\u00a0ou 2026, nous pr\u00e9voyons de couvrir plus de 20\u00a0% des d\u00e9penses du march\u00e9 mondial des m\u00e9dicaments de marque, qui repr\u00e9sente plusieurs milliards de dollars. Et c\u2019est une perspective vraiment passionnante.<\/p>\r\n<p><strong>AB\u00a0:<\/strong> Nous sommes impatients de participer \u00e0 ce voyage. Nous sommes impatients de travailler avec Melanie et l\u2019\u00e9quipe d\u2019EQRx et de commencer \u00e0 vraiment mettre en \u0153uvre notre strat\u00e9gie. C\u2019est \u00e0 ce moment-l\u00e0 que le travail commencera vraiment. Nous sommes tr\u00e8s enthousiastes. Nous aimerions que les patients aient acc\u00e8s \u00e0 ces nouveaux m\u00e9dicaments formidables d\u00e8s que possible, et nous ferons tout notre possible pour y parvenir au cours des prochaines ann\u00e9es, et nous l\u2019esp\u00e9rons au-del\u00e0.<\/p>"],"_content":[""],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_edit_last":["22"],"_wpml_media_duplicate":["1"],"_wpml_media_featured":["1"],"_yoast_wpseo_content_score":["60"],"_yoast_wpseo_estimated-reading-time-minutes":["11"]},"_links":{"self":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/wp-json\/wp\/v2\/perspectives\/15385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/wp-json\/wp\/v2\/media\/15377"}],"wp:attachment":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/fr\/wp-json\/wp\/v2\/media?parent=15385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}